

## **Product datasheet for TR307036**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## PION (GSAP) Human shRNA Plasmid Kit (Locus ID 54103)

#### **Product data:**

**Product Type:** shRNA Plasmids

Product Name: PION (GSAP) Human shRNA Plasmid Kit (Locus ID 54103)

Locus ID: 54103 Synonyms: PION

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format:

Retroviral plasmids

Components: GSAP - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

54103). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

**RefSeq:** <u>NM 017439</u>, <u>NM 001350896</u>, <u>NM 001350897</u>, <u>NM 001350898</u>, <u>NM 001350899</u>,

NM 001350900, NM 001350901, NM 017439.1, NM 017439.2, NM 017439.3, BC101499,

BC110797, BC143549, BM842423, NR 146938, NR 146937, NM 017439.4

UniProt ID: A4D1B5

**Summary:** Accumulation of neurotoxic amyloid-beta is a major hallmark of Alzheimer disease (AD; MIM

104300). Formation of amyloid-beta is catalyzed by gamma-secretase (see PSEN1; MIM 104311), a protease with numerous substrates. PION, or GSAP, selectively increases amyloid-beta production through a mechanism involving its interaction with both gamma-secretase and its substrate, the amyloid-beta precursor protein (APP; MIM 104760) C-terminal fragment

(APP-CTF) (He et al., 2010 [PubMed 20811458]), [supplied by OMIM, Nov 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>.
If you need a special design or shRNA sequence, please utilize our custom shRNA service.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).